The Quantellect read.As of Nov 19, 2026, 9 active firms cover Edgewise Therapeutics Inc: 8 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $36.00 to $60.00, a moderate spread. The average target of $52.63 sits 27% above the current $41.37. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 7 to 8 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.44 next quarter toward $-1.89 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 active firms
Buy
Strong Buy00%
Buy889%
Neutral111%
Sell00%
Strong Sell00%
Based on 9 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$52.63
+27.2% upside
Average target across 8 active firms as of Nov 19, 2026 vs $41.37 current
Highest Target$60.00
Average Target$52.63
Lowest Target$36.00
Detailed analyst forecasts for EWTX
Showing 1–9 of 9 named analysts shown · 9 active firms in the rating projection
As of Nov 19, 2026, 8 of 9 active firms rate EWTX a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
EWTX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.44
Range $-0.53 – $-0.31 · 6 analysts · -5% YoY
Next period, 6 analysts expect Edgewise Therapeutics Inc to earn $-0.44 a share (range $-0.53 – $-0.31), versus $-0.46 a year earlier. Full-year consensus is $7.66, growing to $-1.89 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 6 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $9.5M next year.
Top analysts covering Edgewise Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on EWTX.
#1
Leonid Timashev
RBC Capital · Rank #27
Buy
$59.00+42.6% to target
Overall win rate
52%
+ Follow
#2
Laura Chico
Wedbush · Rank #55
Buy
$53.00+28.1% to target
Overall win rate
46%
+ Follow
#3
Paul Choi
Goldman Sachs · Rank #110
Neutral
$36.00-13.0% to target
Overall win rate
52%
+ Follow
#4
Joseph Schwartz
Leerink Partners · Rank #242
Buy
No targeton EWTX
Overall win rate
36%
+ Follow
#5
Debjit Chattopadhyay
Guggenheim · Rank #248
Buy
$51.00+23.3% to target
Overall win rate
39%
+ Follow
EWTX stock forecast FAQ
What is EWTX's average 12-month price target?+
The 8 active firms with a live target average $52.63 for Edgewise Therapeutics Inc over the next 12 months, ranging from a $60.00 high to a $36.00 low, as of Nov 19, 2026.
Is EWTX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 9 active firms as of Nov 19, 2026, 8 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for EWTX?+
The Street-high target is $60.00 (JP Morgan), and the Street-low is $36.00 (Goldman Sachs). The average of all 8 active-firm targets is $52.63.
How many active Wall Street firms cover EWTX?+
9 active firms have a recognized rating on Edgewise Therapeutics Inc as of Nov 19, 2026, and 8 active firms carry a live 12-month price target.
Who is the most accurate analyst covering EWTX?+
Among analysts who currently cover EWTX, Leonid Timashev of RBC Capital has the strongest overall Quantellect track record (Rank #27). Their current call is Buy with a $59.00 target.
What is Edgewise Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.44 per share (range $-0.53 – $-0.31) across 6 analysts. Full-year EPS is projected at $7.66, rising to $-1.89 the following year.
How much revenue is Edgewise Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $9.5M next year.
Have analysts been upgrading or downgrading EWTX lately?+
As of Nov 19, 2026, 8 of 9 active firms rate EWTX a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their EWTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.